Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma.

Autor: Kupcova K; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic.; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Senavova J; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic.; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Jura F; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic., Herman V; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic.; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Rajmonova A; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic., Pacheco-Blanco M; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic., Chrbolkova T; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic., Hamova I; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic.; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic., Davis RE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Havranek O; First Faculty of Medicine, BIOCEV, Charles University, Prumyslova 595, Prague, 25250, Czech Republic. ondrej.havranek@lf1.cuni.cz.; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. ondrej.havranek@lf1.cuni.cz.

Publikováno v: Experimental hematology & oncology [Exp Hematol Oncol] 2024 Nov 01; Vol. 13 (1), pp. 108. Date of Electronic Publication: 2024 Nov 01.

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion.

Autor: Malarikova D; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic., Jorda R; Department of Experimental Biology, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic., Kupcova K; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.; BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic., Senavova J; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.; BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic., Dolnikova A; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Pokorna E; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Kazantsev D; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Nozickova K; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic., Sovilj D; Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic., Bellanger C; Integrated Research Center in Immunology and Oncology, CRCI2NA, Nantes University, Nantes, France., Chiron D; Integrated Research Center in Immunology and Oncology, CRCI2NA, Nantes University, Nantes, France., Andera L; BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic.; Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.; Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic., Krystof V; Department of Experimental Biology, Faculty of Science, Palacky University Olomouc, Olomouc, Czech Republic., Strnad M; Laboratory of Growth Regulators, Palacky University Olomouc and Institute of Experimental Botany, The Czech Academy of Sciences, Olomouc, Czech Republic., Helman K; Faculty of Informatics and Statistics, Prague University of Economics and Business, Prague, Czech Republic., Klanova M; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic., Trneny M; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic., Havranek O; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic.; BIOCEV LF1 - Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic., Klener P; Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. pavel.klener2@lf1.cuni.cz.; First Department of Internal Medicine - Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic. pavel.klener2@lf1.cuni.cz.

Publikováno v: Experimental hematology & oncology [Exp Hematol Oncol] 2024 Mar 25; Vol. 13 (1), pp. 34. Date of Electronic Publication: 2024 Mar 25.

Microbiota diversity in patients with Diffuse Large B‐Cell Lymphoma and Immune‐Privileged Sites Lymphoma.

Autor: Dlouha, L., Tenglerova, M., Rehakova, J., Brichova, M., Kostovcik, M., Benesova, K., Kverka, M., Heissigerova, J., Svozilkova, P., Ondeckova, I., Senavova, J., Herman, V., Kostovcikova, K., Trneny, M.

Publikováno v: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p285-286, 2p

Machine Learning Algorithms Identify Target Genes and the Molecular Mechanism of Matrine against Diffuse Large B-cell Lymphoma.

Autor: Zhu Y; Department of Traditional Chinese Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China., Ning Z; Department of Cardiology, Shanghai Pudong New District Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China., Li X; Department of Cardiology, Shanghai Pudong New District Zhoupu Hospital, Shanghai University of Medicine & Health Sciences, Shanghai, 201318, China., Lin Z; Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.

Publikováno v: Current computer-aided drug design [Curr Comput Aided Drug Des] 2024; Vol. 20 (6), pp. 847-859.